International Research Journal of Medicine and Biomedical Sciences
Vol.4 (4),pp. 38-41, October, 2019
Available online at https://www.journalissues.org/IRJMBS/
Author(s) retain the copyright of this article. Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution License 4.0 International License.
Hepatitis B reactivation with hepatic decompensation after the use of direct-acting antiviral agents in a patient with chronic Hepatitis B and C coinfection
Po-Yao Hsu*1, Ming-Lun Yeh1,2, Chung-Feng Huang1,2, Chia-Yen Dai1,2 Ming-Lung Yu1,2, Jee-Fu Huang*1,2,and Wan-Long Chuang1,2
1Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University,Kaohsiung, Taiwan.
2Faculty of Internal Medicine, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
*Corresponding Author Email:u9501067(at)gmail.com, jfliver(at)kmu.edu.tw
In recent years, direct-acting antiviral agents (DAAs) have become the major therapy for Hepatitis C virus (HCV) infection and chronic Hepatitis C (CHC). However, Hepatitis B virus (HBV) reactivation (HBVr) remains an important issue among patients with HBV/HCV coinfection when receiving DAAs for CHC. The severity of HBVr-induced Hepatitis may range from a mild to a severe form of liver injury. In this study, we present a rare case of HBVr leading to a decompensated state and jaundice in a 72-year-old man during DAA treatment. His decompensated state subsequent to HBVr, fortunately improved after initiating oral antiviral treatment for HBV. Our case highlights the importance of the pretreatment evaluation of patients for HBV, monitoring potential HBVr, and the initiation of HBV antiviral therapy in HBV/HCV coinfected patients.
Key words: Direct-acting antiviral agents, chronic Hepatitis C, Hepatitis B virus reactivation, decompensation.